Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. The Company was founded in September 1997 by a team of physicians and oncologists from the Technical University of Munich. In 2000, the Company changed to an AG from a GmbH legal structure. In 2011, the subsidiary Heidelberg Pharma Research GmbH was acquired. Heidelberg Pharma was restructured in 2014, which led to the discontinuation of all research and development activities in Munich. The shareholder’s meeting in July 2017 decided to move the registered office of WILEX AG from Munich to Ladenburg and to change the name of the Company to Heidelberg Pharma AG. The subsidiary Heidelberg Pharma GmbH is now named Heidelberg Pharma Research GmbH.
Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Furthermore, Heidelberg Pharma offers preclinical contract research services.
WILEX’s clinical assets MESUPRON® and REDECTANE® have been partnered, while RENCAREX® is available for out-licensing and further development.